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ABSTRACT 
Hepatocellular carcinoma (HCC) is one of the most common cancers, which is mainly a concern in Southeast Asia. 
Apoptosis resistance in HCC is one of the significant factors for hepatocarcinogenesis and tumour progression. Recent 
advances of apoptosis resistance mechanisms in HCC could serve as potential targets for molecular imaging, which 
would be of considerable value to explore the molecular processes involved in HCC progression and to evaluate 
responses of certain anti-HCC therapies. Disruptions in the balance of anti-apoptotic and pro-apoptotic processes have 
been found to be involved in apoptosis resistance in HCC. Loss of response to death receptors, transformation of growth 
factor-β induced apoptosis, upregulation of anti-apoptotic Bcl-2 subgroup, as well as downregulation of pro-apoptotic 
Bax subgroup and BH3-only subgroup, are associated with apoptosis resistance in HCC. Mutation of p53 gene, 
dysregulation of NF-κB and survivin are also of interest because of their contribution to HCC development. In this 
review, the aim is to identify potential targets for molecular imaging of apoptosis resistance in HCC. © 2011 Biomedical 
Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
Molecular imaging, which uses tracers that bind 
specifically to molecular targets [1], is an emerging field 
that aims to integrate patient-specific and disease-
specific molecular information with traditional 
anatomical imaging readouts [2]. Molecular imaging is 
not only based on nuclear medicine, but also on magnetic 
resonance imaging (MRI), computed tomography (CT), 
and the emerging field of optical imaging. It provides 
visualisation in space of normal as well as abnormal 
cellular processes at the molecular or genetic level, rather 
than at the anatomic level [3]. It has its roots both in 
molecular biology and imaging technologies. On one 
hand, progress in our understanding of the molecular 
biology of diseases will accelerate the development of 
molecular imaging and lead to more effective therapeutic 
strategies. On the other hand, development of different 
non-invasive imaging technologies provide the 
technological foundation for molecular imaging. 
Apoptosis, also known as programmed cell death, 
is an indispensable component of normal human growth 
and development, immunoregulation and homeostasis. 
It was characterised by morphological features such as 
cytoplasmic shrinkage, chromatin condensation in the 
nucleus, phosphatidylserine (PS) exposure, plasma 
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Figure 1 Component of apoptosis pathways 
membrane blebbing and disintegration of the cell into 
small fragments (apoptotic bodies) that are engulfed by 
nearby cells [4]. Apoptosis is nature’s primary 
component of cell proliferation and growth. It represents 
a physiological way to eliminate excess cells during liver 
cell development and regeneration [5]. Resistance to 
apoptosis is associated with carcinogenesis and 
progression, during which cells often show alteration in 
the genes regulating apoptosis machinery. Apoptosis can 
also augment the escape of tumour cells from 
surveillance by the immune system [6, 7]. 
Hepatocellular carcinoma (HCC) is one of the most 
common cancers worldwide with the highest prevalence 
in Southeast Asia [8]. The apoptosis resistance of hepatic 
cells was reported to be one of the significant factors for 
hepatocarcinogenesis or tumour progression in HCC [9]. 
However, the apoptosis resistance in HCC is complicated. 
It is necessary to investigate the molecular mechanisms 
responsible for apoptosis resistance contributing to HCC 
development. These molecules can be further used as 
potential targets for molecular imaging to visualise the 
molecular processes in HCC development as well as to 
evaluate the responses of certain anti-HCC therapies.   
This review is an effort to update the recent relevant 
contributions that report molecular targets involved in 
apoptosis resistance in HCC. 
MOLECULAR BIOLOGY 
The molecular biology of apoptosis resistance in 
HCC may offer a road map for the development of 
molecular imaging strategies. They determine the 
regulatory genes and proteins involved in apoptosis 
resistance in HCC that may provide potential targets for 
molecular imaging. 
Component of apoptosis pathway 
There are two distinct pathways of signal 
transduction of apoptosis that exist in mammalian cells 
(Figure  1) [10, 11]. One is the extrinsic cell death 
pathway, which is characterised by the activation of cell 
surface death receptors following binding of their 
specific ligands. It is mediated by death receptors, a 
subgroup of the tumour necrosis factor (TNF) receptor 
superfamily, including CD95 (also known as Fas), TNF-
related apoptosis-inducing ligand (TRAIL), and TNF-R1. 
All death receptors are characterised by an intracellular 
motif called death domain (DD). Death receptor-
mediated cell death is initiated by the recruitment of 
adapter proteins, like Fas-associated death domain 
(FADD), via DD, which then bind to the death domain-
containing caspase-8 or -10, to form the death-inducing 
signaling complex (DISC). DISC formation results in the 
activation of caspase-8, which then directly cleaves and Liu et al. Biomed Imaging Interv J 2011; 7(1):e5   3 
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activates caspase-3, -6, or -7, the executioner enzymes of 
apoptosis. 
The other is the intrinsic or mitochondrial pathway, 
which is initiated by multiple forms of cellular stress, 
including radiation and chemotherapeutic drugs. In this 
pathway, pro-apoptotic Bcl-2 family members Bax and 
Bak translocate to mitochondria. The Bcl-2 homology 
domain 3 only (BH3-only) protein Bid activates Bax and 
Bak to mediate the release of cytochrome c into cytosol. 
This triggers the assembly of the apoptosome (Apaf-1 
and caspase-9) and, subsequently, the activation of 
caspase-3, -6, or -7, and cell death. The X-linked 
inhibitor of apoptosis (XIAP) may bind directly to 
caspases and inhibit their enzymatic activity. The 
inhibitory function of XIAP is countered by the second 
mitochondrial-derived activator of caspase (Smac) and 
Omi/HtrA2, which are also released into cytoplasm. 
These two principle pathways may proceed 
completely independently in many cell types, but there is 
also considerable cross-talk between extrinsic and 
intrinsic pathways [12]. A mechanism by which the 
mitochondrial pathway is engaged, following death 
receptor activation, is through caspase-8-mediated 
cleavage of Bid, a pro-apoptotic member of the Bcl-2 
family. Once cleaved, truncated Bid (tBid) translocates 
to mitochondria, where it can induce the release of 
cytochrome c, SMAC and Omi/HtrA2. In this manner, 
death receptor signals may be amplified through 
formation and activation of the apoptosome, which can 
increase the activation of effector caspases. 
Regulation of death-receptor pathway 
Tumourigenic disruption in death-receptor pathway 
or extrinsic pathway occurs less frequently than in 
mitochondria pathway or intrinsic pathway. Nevertheless, 
tumour cells are often resistant to death-receptor-
mediated apoptosis. Furthermore, mutations in CD95 
(Fas), TRAIL receptor and downstream signaling 
pathway do occur in cancer [13]. 
(1)  Fas: The majority of HCC show one or more 
alterations in the Fas molecules, which inhibit Fas-
mediated apoptosis [14]. Loss of response to Fas in 
HCC may be produced either by downregulation of 
Fas expression [14, 15], concomitant with decreased 
expression of downstream molecules, such as 
FADD or caspase-8 (also known as FLICE) [15], or 
by upregulation or overactivation of molecules that 
counteract its pro-apoptotic effect, including nuclear 
factor-kappa B (NF-κB), Bcl-2 or Bcl-XL [16–18]. 
The status of Fas and Fas ligand (FasL) expression 
can also predict hepatocellular carcinoma 
recurrence [19]. 
(2)  TRAIL: TRAIL and specific agonistic antibodies 
have attracted considerable attention for their 
potential use in selective induction of apoptosis in 
activated stellate cells, as well as in virus-infected 
and malignant hepatocytes without associated 
collateral damage to normal hepatocytes [20]. Loss 
of TRAIL-R may promote growth of neoplastic 
changes in liver, and this may possibly be a result 
of blocked apoptosis in HCC [21]. HCC 
constitutively express TRAIL mRNA and proteins, 
but most HCC are insensitive towards TRAIL-
mediated apoptosis. Hepatitis B virus core protein 
[22] and overactivation of NF-κB and Bcl-XL [23] 
in HCC have been indicated to restrain the 
TRAIL-induced apoptosis. Efficacy of TRAIL-
induced apoptosis in tumours in vivo has been 
reported to be monitored by dual enzyme substrate 
(Rluc/Fluc) imaging, which demonstrated its role 
in inducing apoptosis in neoplastic cells [24]. 
(3)  cFLIP: Cellular FLICE/caspase-8 inhibitory 
protein (cFLIP), which is an intracellular inhibitor 
of caspase-8 activation that potently inhibits death 
receptor-mediated apoptosis, was found to be 
constitutively expressed in all human HCC cell 
lines, and was expressed more in human HCC 
tissues than in non-tumour liver tissues [25].  
(4)  BRE: Brain and reproductive organ-expressed 
protein (BRE), as a death receptor associated 
protein, specifically down-modulates death 
receptor-mediated apoptosis by inhibiting 
activation of the mitochondrial apoptotic pathway. 
It was found to bind the death receptors TNF-R1 
and Fas, and upon over-expression, conferred 
resistance to apoptosis induced by TNF-α, anti-Fas 
agonist antibody, cycloheximide, and a variety of 
stress-related stimuli [26]. Thus, BRE is 
considered anti-apoptotic in vivo and may promote 
tumourigenesis when overexpressed, with marked 
over-expression of BRE detected in the majority of 
HCC [27]. 
Regulation of mitochondrial pathway 
The Bcl-2 proteins are the crucial checkpoints for 
the intrinsic or mitochondrial pathways [28]. Bcl-2 
family proteins are structurally defined by their Bcl-2 
homology domain (BH domains) into multidomains and 
BH3-only, and are functionally categorised into anti-
apoptotic and pro-apoptotic [29]. Bcl-2 family members 
are generally categorised into three subgroups. The first 
group includes Bcl-2, Bcl-XL, Mcl-1, Bcl-w, Bcl-
B/Nrh/NR13 and Bfl-1/Bcl-2A1/GRS. These molecules 
contain multi-BH domains and function to inhibit 
apoptosis. The second group also contains multi-BH 
domains but the proteins function to promote apoptosis. 
These proteins include Bax, Bak, Bok/Mtd and Bcl-XS. 
The third group contains only a BH3 domain and it 
includes Bid, BAD, Bik/Nbk, Bim/Bod, PUMA, Noxa, 
Hrk/DP5, Bmf, Spike and Bnip proteins. The BH3-only 
proteins bind and regulate the pro-survival Bcl-2 family 
members to promote apoptosis.  
Many of the genetic alterations observed in HCC 
lead to an imbalance in pro-apoptotic and anti-apoptotic 
members of the Bcl-2 family [30]. 
(1)  Bcl-2 subgroup: Bcl-XL and Mcl-1 are over-
expressed in a great percentage of HCC cells, 
including HepG2, Hep3B, Huh7 cells and human 
HCC tissues. The expression of Mcl-1 is correlated 
with Bcl-XL in HCC tissues [31, 32]. Bcl-XL is Liu et al. Biomed Imaging Interv J 2011; 7(1):e5   4 
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also a significant prognostic factor for disease 
progression and poorer survival in human HCC [33]. 
(2)  Bax subgroup: In contrast, pro-apoptotic members 
of the family, such as Bax or Bcl-XS are 
downregulated in HCC with dysfunction in the 
p53 pathway [33]. 
(3)  BH3-only subgroup: Members of the BH3-only 
family, such as Bid, show decreased expression in 
HCC related to hepatitis B virus X protein or 
hepatitis C virus polyprotein [34]. Bid can also 
block the inhibitory effect of Bcl-2 on Fas-
mediated apoptosis of HCC cell line BEL-7404 
cells [35]. 
(4)  XIAP: XIAP, a well-known inhibitor of caspases, 
was reported to be overexpressed in HCC, and 
inversely correlated with apoptosis [36]. Further, 
studies in established HCC cell lines with different 
metastatic capabilities indicated a correlation of 
metastasis with resistance to apoptosis and 
increased expression of XIAP [37]. 
Caspases are attractive targets because of their 
central role in the execution of cell death [38]. Both the 
death receptor and mitochondrial pathways of apoptosis 
eventually activate several effector caspases [38]. As 
caspases play vital roles in mediating the initiation and 
propagation of the apoptotic cascade, the ability to image 
caspases activation non-invasively will provide an 
opportunity to evaluate the regulation of apoptosis status 
in vivo. 
Several strategies are emerging to image the 
activation of caspases. Caspase activities have been 
imaged using exogenous radio-labeled imaging agents. 
In a series of cell-based experiments, two radio-iodinated 
peptides selective for caspase-3 were found to have 
increased uptake and retention within apoptotic cells [39]. 
Zhou  et al. [40] employed an 
18F-radio-labeled isatin 
sulfonamide analog that targets activated caspase-3. This 
agent was used with micro-PET imaging to visualise 
cyclohexamide-induced hepatic apoptosis in a rat model. 
One strategy utilised a polymer conjugated to a near-
infrared fluorescence effector caspase-specific peptide to 
create a biocompatible, cell-permeable, autoquenched 
nanoparticle to image apoptosis in real time in living 
cells [41]. Another approach successfully employed a 
novel caspase-1 specific, activatable, near-infrared 
fluorescent probe as a means to image apoptosis in mice 
models of apoptosis [42]. Recent reports have 
demonstrated that caspase-specific fluorescently labeled 
activity-based probes (ABPs) have the potential to be 
used for non-invasive imaging of apoptosis in both pre-
clinical and clinical settings [43]. Although work on 
imaging the activation of caspases is promising, there is 
still limited animal data so far and no human data. 
Regulation of p53 
Human tumours harbour mutation, which renders 
them resistant to apoptosis. The p53 gene is one of the 
most frequently mutated genes in tumour cells [12]. The 
tumour suppressor protein p53, a transcription factor, can 
prevent cells from growth and division, thus mediating 
cell-cycle arrest, DNA repair and apoptosis, after the p53 
gene has been activated by multiple forms of cellular 
stresses [44]. Abnormalities of p53 are considered a 
predisposing factor for hepatocarcinogenesis [44]. 
The p53 gene is frequently mutated in high-grade 
HCC [45]. Bressac et al. [46] studied the p53 gene and 
protein in seven HCC-derived cell lines, and found that 
six of them showed p53 abnormalities, suggesting that 
alterations in p53 may be important events in the 
transformation of hepatocytes into the malignant 
phenotype [47]. Inactivation of the p53 gene also plays 
an important role in the progression of chronic liver 
damage to HCC by directly or indirectly inducing 
chromosome instability, cell proliferation and 
neovascularisation [48]. It was reported that attenuated 
p53 function and telomere-induced chromosomal 
instability play a critical and cooperative role in the 
progression of chronic liver damage to HCC, and the loss 
of p53 expression or the presence of abnormal forms of 
the protein is frequently associated with HCC cell lines 
[49]. Furthermore, it was reported that p53-dependent 
gene expression has already been imaged in vivo with 
positron emission tomography (PET) and by in situ 
fluorescence [50]. A retroviral vector (Cis-p53/TKeGFP) 
was generated by placing the herpes simplex virus (HSV) 
type 1 thymidine kinase (tk) and enhanced green 
fluorescent protein (GFP) fusion gene under the control 
of a p53-specific response element. Apoptosis-induced 
upregulation of p53 transcriptional activity was 
demonstrated by using PET imaging, which would be of 
considerable value in assessing novel therapeutic 
approaches that are mediated through p53-dependent 
pathways. 
Regulation of NF-κB in inflammation 
Recent studies have indicated that virus activity may 
drive tumour progression [51] and NF-κB is considered 
to be an important molecular link between chronic 
inflammation and cancer development [6, 52, 53]. NF-
κB was initially discovered as a transcription factor in 
the nucleus of B cells that binds to the enhancer of the 
kappa light chain of immunoglobulin, and it has since 
been shown to be expressed ubiquitously in the 
cytoplasm of all types of cells [54]. Its family members 
may accumulate in the cytoplasm and reach the nucleus 
where they transactivate several growth-related genes 
and anti-apoptotic gene [55]. NF-κB suppresses 
apoptosis by inducing the expression of a number of 
genes whose products inhibit apoptosis, including IAPs, 
cFLIP, TNF receptor associated factor 1 (TRAF1) and 
TRAF2. Two typical prosurvival NF-κB targets are Bcl-
XL, an anti-apoptotic member of Bcl-2 family, and XIAP, 
a member of the caspases inhibitor, which are frequently 
overexpressed in HCC [56]. These anti-apoptotic 
proteins have been found to work in a coordinated 
fashion to block apoptosis at multiple steps along the 
apoptotic cascade or to regulate other pro- or anti-
apoptotic pathways [57]. Transactivating forms of NF-
κB may upregulate the expression of several other genes Liu et al. Biomed Imaging Interv J 2011; 7(1):e5   5 
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involved in anti-apoptosis, cell proliferation and invasion, 
and drug resistance (e.g., Bcl-2, Bcl-XL, cyclin D1, c-
Myc, IL-6, COX-2, iNOS, MMPs) [37]. Moreover, other 
hallmarks of cancer such as sustained angiogenesis, 
tissue invasion, and metastasis were also reported to be 
at least partially dependent on NF-κB signaling [58, 59]. 
HCC commonly develops in the background of 
chronic hepatitis, in which NF-κB activation is often 
observed [60]. Certain studies have implicated that 
members of NF-κB family act in both HBV- and HCV-
induced neoplastic development of liver [61]. 
Overproduction of inflammatory cytokines and growth 
factors during the early stages of hepatocarcinogenesis 
deregulates the inducible nitric oxide synthase, inhibition 
κB (IκB) kinase, and NF-κB axis [55]. It has also been 
suggested that TNF-α has a central role in activating NF-
κB and in protecting transformed hepatocytes against 
apoptosis [62]. 
The TGF-β signal pathway 
The transforming growth factor-beta (TGF-β) 
signaling pathway is a key player in metazoan biology, 
and its misregulation can result in tumour development 
[63]. Pathological forms of TGF-β signaling promote 
tumour growth and invasion, evasion of immune 
surveillance, and cancer cell dissemination and 
metastasis [63]. TGF-β1 is also a key cytokine in the 
regulation of hepatic apoptosis, and act via the Smad 
pathway to initiate gene transcription and activation of 
caspases [64]. Blocking TGF-β can upregulate E-
cadherin, and reduce migration and invasion of HCC 
[65]. Huang et al. [65] reported that the HCC might also 
overexpress a specific set of microRNAs that would 
allow the escape from TGF-β-induced apoptosis, which 
might be a prerequisite for HCC progression [66]. 
A novel protein--survivin 
Survivin is a novel protein and also an attractive 
target which is involved in multiple signaling 
mechanisms controlling tumour maintenance [67]. 
Survivin is a member of the inhibitor of apoptosis (IAP) 
family of proteins, of which eight members are known to 
exist, i.e., XIAP, NAIP, c-IAP1, c-IAP2, livin, ILP2, 
BRUCE and survivin [68]. IAPs prevent cell death by 
acting as endogenous suppressors of caspase activity [69]. 
Multiple  in vitro and in vivo studies have shown that 
survivin inhibits cell death, especially apoptosis, through 
both intrinsic and extrinsic mediators of apoptosis, 
including IL-3 withdrawal, Fas stimulation, TRAIL, 
overexpression of Bax, p53, as well as caspase-3, -7 and 
-8, to name a few [70]. Importantly, it is recognised that 
survivin not only inhibits apoptosis, but also, as a 
component of the chromosomal passenger complex, 
favours cancer cell proliferative activity [36]. Survivin is 
rarely expressed in normal healthy adult tissues, but 
upregulated in the majority of cancers [70]. It was found 
to be overexpressed in HCC cell lines and tissues [71], 
and might play a pivotal role in metastasis of HCC [72]. 
It may also be positively correlated with a high risk of 
disease recurrence and poor prognosis [73]. 
IMAGING TECHNOLOGIES  
There are mainly three imaging technologies used 
for molecular imaging of apoptosis, namely MRI, 
nuclear imaging (quantitative autoradiography, gamma 
camera, single-photon emission computed tomography 
(SPECT) and PET), and in vivo optical imaging [74–81]. 
Several ligands with specific, high-affinity binding 
to phosphatidylserine (PS) have been exploited as agents 
capable of detecting apoptosis. The most investigated 
ligand is annexin V, which binds with high affinity to PS 
[82]. Annexin V-functionalised cross-linked iron oxide 
(CLIO) was designed as a contrast agent for MRI, which 
was additionally labeled with Cy5.5 to allow co-
localisation with optical imaging techniques [83]. Zhao 
et al. [84] demonstrated success by labeling the C2-
domain of a PS binding protein, synaptotagmin I, with 
superparamagnetic iron oxide nanoparticles (SPIOs). 
This SPIO-labeled protein was shown to bind to 
apoptotic cells in vitro and detected by MRI. 
Nuclear imaging approaches have the advantages of 
high intrinsic sensitivity, unlimited depth penetration, 
and a broad range of clinically-available and clinically-
tested molecular imaging agents [2]. For example, 
99mTc-
labeled annexin V is the most extensively investigated 
and used in vivo in detecting apoptosis. Numerous 
99mTc-
annexin V-based radioligands have been developed and 
clinical trails have already been undertaken [85]. Yagle 
et al. [86] also indicated that 
18F-annexin V binds 
specifically to apoptotic tissues in rat model of liver 
apoptosis, which may be useful in early assessment of 
the clinical response to cancer therapy. Some other 
radioligands for PET imaging of apoptosis were 
proposed, such as 
123I-annexin V [87], 
11C-annexin V 
[88]. 
Optical techniques for molecular imaging include 
optical coherence tomography, fluorescence or 
luminescence imaging, and infrared imaging, which are 
commonly used for pre-clinical cellular and molecular 
imaging in animals [89]. Besides radionuclide imaging, 
biotin-labelled and fluorescent annexin V have been 
applied in the detection and confirmation of apoptosis. 
Fluorescent labeled annexin V has been applied to image 
cardiomyocyte apoptosis in single cardiomyocytes [90]. 
Annexin V was successfully conjugated with a near-
infrared fluorochrome, cyanine-5.5 (Cy5.5), and applied 
in detecting apoptotic cells in vivo [91, 92]. Jiang et al. 
[93] developed protease reporter molecules based on a 
fluorophore (Cy5) linked to a polycationic cell-permeant 
peptide, specific protease cleavage site, and polyanionic 
peptide. FITC-annexin V is currently used widely as a 
research reagent for apoptosis detection in flow 
cytometry [92, 93]. Liu et al. Biomed Imaging Interv J 2011; 7(1):e5   6 
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CONCLUSION AND FUTURE PERSPECTIVES 
Molecular imaging is a rapidly emerging field in 
biomedical research to sense biological processes such as 
gene expression, apoptosis, etc. The recognition that 
apoptosis resistance acts as a pathogenic mechanism and 
contributes to tumourigenesis has gained increasing 
interest in molecular imaging. In the past couple of years, 
many strategies about apoptosis resistance in HCC have 
been reported. Overexpression of anti-apoptotic proteins, 
such as cFLIP, BRE, Bcl-2 subgroup, XIAP, survivin; 
downregulation of pro-apoptotic proteins, such as Fas, 
TRAIL, Bax subgroup, BH3-only subgroup; as well as 
mutation of p53 gene, activation of NF-κB and escape 
from TGF-β-induced apoptosis, all contribute to 
apoptosis resistance in HCC cells and tissues. The 
identification of these genes and proteins that regulate 
apoptosis resistance in HCC and the potential application 
of these molecules as imaging targets could add critical 
insights into inducing sensitivity to apoptotic pathways 
in HCC, as well as allow the noninvasive evaluation of 
the efficacy of therapeutic options for HCC in the near 
future. 
Technologies like MRI, nuclear medicine, and 
optical imaging techniques are making significant 
contributions to molecular imaging. It will also be 
important to continuing developing technologies that 
combine non-invasive anatomical and functional imaging. 
These sensitive imaging-based assays would provide a 
spatial and temporal dimension to monitor molecular 
processes if the molecular probes of the genes and 
proteins that regulate apoptosis resistance in HCC were 
labeled with radionuclides or fluorescence protein, and 
would be of considerable value in the understanding of 
apoptosis resistance in HCC. However, the study of MRI, 
nuclear medicine techniques, and optical imaging 
techniques to detect and track apoptosis in vivo has only 
just begun. Further work is needed to prove that those 
techniques would be effective in the detection of 
apoptosis resistance in HCC, and their clinical 
applicability still remains to be defined. 
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